NSCLC immune biomarkers
Nov 17, 2023
The Next Chapter in NSCLC Treatment Space: Recent Discoveries and Innovations
Lung cancer is the leading cause of cancer death in both men and women around the world. It is expected that 127K people will die from this disease in the United States in 2023 (67K men and 60K women). NSCLC is the most common type of lung cancer, accounting for over 85% of all cases. As per DelveInsight anal...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
